Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 149

1.

Culprit-Only Artery Versus Multivessel Disease.

Paradies V, Smits PC.

In: Watson TJ, Ong PJL, Tcheng JE, editors. Primary Angioplasty: A Practical Guide [Internet]. Singapore: Springer; 2018. Chapter 13.
2018 Jul 14.

2.

Impact of Diabetes Mellitus in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents.

Baber U, Stefanini GG, Giustino G, Stone GW, Leon MB, Sartori S, Aquino M, Steg PG, Windecker S, Wijns W, Serruys PW, Valgimigli M, Morice MC, Camenzind E, Weisz G, Smits PC, Kandzari DE, von Birgelen C, Dangas GD, Galatius S, Jeger RV, Kimura T, Mikhail GW, Itchhaporia D, Mehta L, Ortega R, Kim HS, Kastrati A, Chieffo A, Mehran R.

Circ Cardiovasc Interv. 2019 Jul;12(7):e007734. doi: 10.1161/CIRCINTERVENTIONS.118.007734. Epub 2019 Jul 10.

PMID:
31288561
3.

Derivation and external validation of a novel risk score for prediction of 30-day mortality after percutaneous coronary intervention.

Brener SJ, Leon MB, Serruys PW, Smits PC, von Birgelen C, Mehran R, Kirtane AJ, Witzenbichler B, Rinaldi MJ, Metzger DC, Mazzaferri EL Jr, Zhang Z, Stone GW; Collaborators.

EuroIntervention. 2019 Aug 9;15(6):e551-e557. doi: 10.4244/EIJ-D-19-00262.

4.

Absorb Bioresorbable Scaffold Versus Xience Metallic Stent for Prevention of Restenosis Following Percutaneous Coronary Intervention in Patients at High Risk of Restenosis: Rationale and Design of the COMPARE ABSORB Trial.

Chang CC, Onuma Y, Achenbach S, Barbato E, Chevalier B, Cook S, Dudek D, Escaned J, Gori T, Kočka V, Tarantini G, West NEJ, Morice MC, Tijssen JGP, van Geuns RJ, Smits PC; COMPARE ABSORB trial investigators.

Cardiovasc Revasc Med. 2019 Jul;20(7):577-582. doi: 10.1016/j.carrev.2019.04.013. Epub 2019 Apr 16.

5.

Abluminal biodegradable polymer biolimus-eluting versus durable polymer everolimus-eluting stent in patients with diabetes mellitus: 5 years follow-up from the COMPARE II trial.

Paradies V, Vlachojannis GJ, Royaards KJ, Wassing J, van der Ent M, Smits PC.

Int J Cardiol. 2019 Sep 1;290:40-44. doi: 10.1016/j.ijcard.2019.04.054. Epub 2019 May 3.

6.

Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trial.

Zaman A, de Winter RJ, Kogame N, Chang CC, Modolo R, Spitzer E, Tonino P, Hofma S, Zurakowski A, Smits PC, Prokopczuk J, Moreno R, Choudhury A, Petrov I, Cequier A, Kukreja N, Hoye A, Iniguez A, Ungi I, Serra A, Gil RJ, Walsh S, Tonev G, Mathur A, Merkely B, Colombo A, Ijsselmuiden S, Soliman O, Kaul U, Onuma Y, Serruys PW; TALENT trial investigators.

Lancet. 2019 Mar 9;393(10175):987-997. doi: 10.1016/S0140-6736(18)32467-X. Epub 2019 Feb 28.

PMID:
30827782
7.

Cracking the Calcified Plaque.

Smits PC.

Cardiovasc Revasc Med. 2019 Feb;20(2):91-92. doi: 10.1016/j.carrev.2019.01.015. No abstract available.

PMID:
30799046
8.

Fractional flow reserve-guided percutaneous coronary intervention vs. medical therapy for patients with stable coronary lesions: meta-analysis of individual patient data.

Zimmermann FM, Omerovic E, Fournier S, Kelbæk H, Johnson NP, Rothenbühler M, Xaplanteris P, Abdel-Wahab M, Barbato E, Høfsten DE, Tonino PAL, Boxma-de Klerk BM, Fearon WF, Køber L, Smits PC, De Bruyne B, Pijls NHJ, Jüni P, Engstrøm T.

Eur Heart J. 2019 Jan 7;40(2):180-186. doi: 10.1093/eurheartj/ehy812.

9.

Outcomes Among Diabetic Patients Undergoing Percutaneous Coronary Intervention With Contemporary Drug-Eluting Stents: Analysis From the BIONICS Randomized Trial.

Konigstein M, Ben-Yehuda O, Smits PC, Love MP, Banai S, Perlman GY, Golomb M, Ozan MO, Liu M, Leon MB, Stone GW, Kandzari DE.

JACC Cardiovasc Interv. 2018 Dec 24;11(24):2467-2476. doi: 10.1016/j.jcin.2018.09.033.

PMID:
30573057
10.

To screen and treat silent ischemia: A tough dilemma.

Smits PC.

Cardiovasc Revasc Med. 2018 Oct;19(7 Pt A):738-739. doi: 10.1016/j.carrev.2018.10.008. No abstract available.

PMID:
30420095
11.

Angiographic and Midterm Outcomes of Bioresorbable Vascular Scaffold for Coronary Bifurcation Lesions.

Paradies V, Vlachojannis GJ, Royaards KJ, Wassing J, van der Ent M, Smits PC.

Am J Cardiol. 2018 Dec 15;122(12):2035-2042. doi: 10.1016/j.amjcard.2018.09.003. Epub 2018 Sep 13.

PMID:
30360886
12.

Cardiovascular and Noncardiovascular Death After Percutaneous Coronary Intervention: Insights From 32 882 Patients Enrolled in 21 Randomized Trials.

Brener SJ, Tarantini G, Leon MB, Serruys PW, Smits PC, von Birgelen C, Crowley A, Ben-Yehuda O, Stone GW.

Circ Cardiovasc Interv. 2018 Jul;11(7):e006488. doi: 10.1161/CIRCINTERVENTIONS.118.006488.

PMID:
30006331
13.

One-year efficacy and safety of routine prasugrel in patients with acute coronary syndromes treated with percutaneous coronary intervention: results of the prospective rijnmond collective cardiology research study.

Yetgin T, Boersma E, Smits PC, de Vries AG, Huijskens E, Zijlstra F, van der Linden MMJM, van Geuns RJM; CCR Study Investigators.

Neth Heart J. 2018 Aug;26(7-8):393-400. doi: 10.1007/s12471-018-1126-0.

14.

Mid-term outcomes of the Absorb BVS versus second-generation DES: A systematic review and meta-analysis.

Felix CM, van den Berg VJ, Hoeks SE, Fam JM, Lenzen M, Boersma E, Smits PC, Serruys PW, Onuma Y, van Geuns RJM.

PLoS One. 2018 May 9;13(5):e0197119. doi: 10.1371/journal.pone.0197119. eCollection 2018. Review.

15.

Mortality Following Nonemergent, Uncomplicated Target Lesion Revascularization After Percutaneous Coronary Intervention: An Individual Patient Data Pooled Analysis of 21 Randomized Trials and 32,524 Patients.

Palmerini T, Della Riva D, Biondi-Zoccai G, Leon MB, Serruys PW, Smits PC, von Birgelen C, Ben-Yehuda O, Généreux P, Bruno AG, Jenkins P, Stone GW.

JACC Cardiovasc Interv. 2018 May 14;11(9):892-902. doi: 10.1016/j.jcin.2018.01.277. Epub 2018 Apr 18.

16.

A prospective randomised trial comparing the novel ridaforolimus-eluting BioNIR stent to the zotarolimus-eluting Resolute stent: six-month angiographic and one-year clinical results of the NIREUS trial.

Paradies V, Ben-Yehuda O, Jonas M, Banai S, Iñiguez A, Perlman GY, Kandzari DE, Stone GW, Smits PC.

EuroIntervention. 2018 May 20;14(1):86-93. doi: 10.4244/EIJ-D-17-00890.

17.

Effect of Increasing Stent Length on 3-Year Clinical Outcomes in Women Undergoing Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents: Patient-Level Pooled Analysis of Randomized Trials From the WIN-DES Initiative.

Chandrasekhar J, Baber U, Sartori S, Stefanini GG, Sarin M, Vogel B, Farhan S, Camenzind E, Leon MB, Stone GW, Serruys PW, Wijns W, Steg PG, Weisz G, Chieffo A, Kastrati A, Windecker S, Morice MC, Smits PC, von Birgelen C, Mikhail GW, Itchhaporia D, Mehta L, Kim HS, Valgimigli M, Jeger RV, Kimura T, Galatius S, Kandzari D, Dangas G, Mehran R.

JACC Cardiovasc Interv. 2018 Jan 8;11(1):53-65. doi: 10.1016/j.jcin.2017.11.020.

18.

Effects of Body Mass Index on Clinical Outcomes in Female Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From a Patient-Level Pooled Analysis of Randomized Controlled Trials.

Faggioni M, Baber U, Afshar AE, Giustino G, Sartori S, Sorrentino S, Steg PG, Stefanini GG, Windecker S, Leon MB, Stone GW, Wijns W, Serruys PW, Valgimigli M, Camenzind E, Weisz G, Smits PC, Kandzari DE, Galatius S, Von Birgelen C, Jeger RV, Mikhail GW, Itchhaporia D, Mehta L, Ortega R, Kim HS, Kastrati A, Chieffo A, Dangas GD, Morice MC, Mehran R.

JACC Cardiovasc Interv. 2018 Jan 8;11(1):68-76. doi: 10.1016/j.jcin.2017.06.060. Epub 2017 Dec 13.

19.

Serial Assessment of Strut Coverage of Biodegradable Polymer Drug-Eluting Stent at 1, 2, and 3 Months After Stent Implantation by Optical Frequency Domain Imaging: The DISCOVERY 1TO3 Study (Evaluation With OFDI of Strut Coverage of Terumo New Drug Eluting Stent With Biodegradable Polymer at 1, 2, and 3 Months).

Chevalier B, Smits PC, Carrié D, Mehilli J, Van Boven AJ, Regar E, Sawaya FJ, Chamié D, Kraaijeveld AO, Hovasse T, Vlachojannis GJ.

Circ Cardiovasc Interv. 2017 Dec;10(12). pii: e004801. doi: 10.1161/CIRCINTERVENTIONS.116.004801.

20.

Long-term invasive follow-up of bioresorbable vascular scaffold: Optical Coherence Tomography assessment of jailed side branches.

Paradies V, Smits PC, Vachojannis GJ, Royaards KJ, Wassing J, van der Ent M.

Cardiovasc Revasc Med. 2018 Apr;19(3 Pt A):279-285. doi: 10.1016/j.carrev.2017.09.001. Epub 2017 Sep 10.

PMID:
29066339
21.

Two-year clinical outcomes of patients treated with overlapping absorb scaffolds: An analysis of the ABSORB EXTEND single-arm study.

Costa JR Jr, Abizaid A, Bartorelli AL, Whitbourn R, Serruys PW, Smits PC; ABSORB EXTEND investigators.

Catheter Cardiovasc Interv. 2018 Jun;91(7):1202-1209. doi: 10.1002/ccd.27223. Epub 2017 Oct 10.

PMID:
29024452
22.

Functional comparison between the BuMA Supreme biodegradable polymer sirolimus-eluting stent and a durable polymer zotarolimus-eluting coronary stent using quantitative flow ratio: PIONEER QFR substudy.

Asano T, Katagiri Y, Collet C, Tenekecioglu E, Miyazaki Y, Sotomi Y, Amoroso G, Aminian A, Brugaletta S, Vrolix M, Hernandez-Antolín R, van de Harst P, Íñiguez-Romo A, Janssens L, Smits PC, Wykrzykowska JJ, Ribeiro VG, Pereira H, da Silva PC, Piek JJ, Reiber JHC, von Birgelen C, Sabaté M, Onuma Y, Serruys PW.

EuroIntervention. 2018 Aug 3;14(5):e570-e579. doi: 10.4244/EIJ-D-17-00461.

23.

First-in-man randomised comparison of the BuMA Supreme biodegradable polymer sirolimus-eluting stent versus a durable polymer zotarolimus-eluting coronary stent: the PIONEER trial.

von Birgelen C, Asano T, Amoroso G, Aminian A, Brugaletta S, Vrolix M, Hernandez-Antolín R, van de Harst P, Iñiguez A, Janssens L, Smits PC, Wykrzykowska JJ, Ribeiro VG, Pereira H, da Silva PC, Piek JJ, Onuma Y, Serruys PW, Sabaté M.

EuroIntervention. 2018 Apr 20;13(17):2026-2035. doi: 10.4244/EIJ-D-17-00462.

24.

Randomized Comparison of Ridaforolimus- and Zotarolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease: Primary Results From the BIONICS Trial (BioNIR Ridaforolimus-Eluting Coronary Stent System in Coronary Stenosis).

Kandzari DE, Smits PC, Love MP, Ben-Yehuda O, Banai S, Robinson SD, Jonas M, Kornowski R, Bagur R, Iniguez A, Danenberg H, Feldman R, Jauhar R, Chandna H, Parikh M, Perlman GY, Balcells M, Markham P, Ozan MO, Genereux P, Edelman ER, Leon MB, Stone GW.

Circulation. 2017 Oct 3;136(14):1304-1314. doi: 10.1161/CIRCULATIONAHA.117.028885. Epub 2017 Aug 9.

25.

Fractional Flow Reserve-Guided Multivessel Angioplasty in Myocardial Infarction.

Smits PC, Boxma-de Klerk BM.

N Engl J Med. 2017 Jul 27;377(4):397-8. doi: 10.1056/NEJMc1706275. No abstract available.

PMID:
28745981
26.

Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration.

Giustino G, Harari R, Baber U, Sartori S, Stone GW, Leon MB, Windecker S, Serruys PW, Kastrati A, Von Birgelen C, Kimura T, Stefanini GG, Dangas GD, Wijns W, Steg PG, Morice MC, Camenzind E, Weisz G, Smits PC, Sorrentino S, Sharma M, Farhan S, Faggioni M, Kandzari D, Galatius S, Jeger RV, Valgimigli M, Itchhaporia D, Mehta L, Kim HS, Chieffo A, Mehran R.

JAMA Cardiol. 2017 Aug 1;2(8):855-862. doi: 10.1001/jamacardio.2017.1978.

27.

Biodegradable Polymer Biolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With Coronary Artery Disease: Final 5-Year Report From the COMPARE II Trial (Abluminal Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent).

Vlachojannis GJ, Smits PC, Hofma SH, Togni M, Vázquez N, Valdés M, Voudris V, Slagboom T, Goy JJ, den Heijer P, van der Ent M.

JACC Cardiovasc Interv. 2017 Jun 26;10(12):1215-1221. doi: 10.1016/j.jcin.2017.02.029. Epub 2017 May 31.

28.

Potentially increased incidence of scaffold thrombosis in patients treated with Absorb BVS who terminated DAPT before 18 months.

Felix CM, Vlachojannis GJ, IJsselmuiden AJJ, Fam JM, Smits PC, Lansink WJ, Diletti R, Zijlstra F, Regar ES, Boersma E, Onuma Y, van Geuns RJM.

EuroIntervention. 2017 Jun 2;13(2):e177-e184. doi: 10.4244/EIJ-D-17-00119.

30.

Fractional Flow Reserve-Guided Multivessel Angioplasty in Myocardial Infarction.

Smits PC, Abdel-Wahab M, Neumann FJ, Boxma-de Klerk BM, Lunde K, Schotborgh CE, Piroth Z, Horak D, Wlodarczak A, Ong PJ, Hambrecht R, Angerås O, Richardt G, Omerovic E; Compare-Acute Investigators.

N Engl J Med. 2017 Mar 30;376(13):1234-1244. doi: 10.1056/NEJMoa1701067. Epub 2017 Mar 18.

31.

Everolimus-eluting bioresorbable vascular scaffolds for treatment of complex chronic total occlusions.

Fam JM, Ojeda S, Garbo R, Latib A, La Manna A, Vaquerizo B, Boukhris M, Vlachojannis GJ, van Geuns RJ, Ezhumalai B, Kawamoto H, van der Sijde J, Felix C, Pan M, Serdoz R, Boccuzzi GG, De Paolis M, Sardella G, Mancone M, Tamburino C, Smits PC, Di Mario C, Seth A, Serra A, Colombo A, Serruys P, Galassi AR, Zijlstra F, Van Mieghem NM, Diletti R.

EuroIntervention. 2017 Jun 20;13(3):355-363. doi: 10.4244/EIJ-D-16-00253.

32.

Randomized Multicenter Trial Investigating Angiographic Outcomes of Hybrid Sirolimus-Eluting Stents With Biodegradable Polymer Compared With Everolimus-Eluting Stents With Durable Polymer in Chronic Total Occlusions: The PRISON IV Trial.

Teeuwen K, van der Schaaf RJ, Adriaenssens T, Koolen JJ, Smits PC, Henriques JP, Vermeersch PH, Tjon Joe Gin RM, Schölzel BE, Kelder JC, Tijssen JG, Agostoni P, Suttorp MJ.

JACC Cardiovasc Interv. 2017 Jan 23;10(2):133-143. doi: 10.1016/j.jcin.2016.10.017.

33.

Coronary artery aneurysm after sequential stenting with bioresorbable vascular scaffolds.

Paradies V, Smits PC.

Coron Artery Dis. 2017 May;28(3):263-265. doi: 10.1097/MCA.0000000000000451. No abstract available.

PMID:
27845999
35.

Randomised comparison of a bioresorbable everolimus-eluting scaffold with a metallic everolimus-eluting stent for ischaemic heart disease caused by de novo native coronary artery lesions: the 2-year clinical outcomes of the ABSORB II trial.

Chevalier B, Onuma Y, van Boven AJ, Piek JJ, Sabaté M, Helqvist S, Baumbach A, Smits PC, Kumar R, Wasungu L, Serruys PW.

EuroIntervention. 2016 Oct 20;12(9):1102-1107. doi: 10.4244/EIJY16M08_01.

36.

Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration.

Giustino G, Mastoris I, Baber U, Sartori S, Stone GW, Leon MB, Serruys PW, Kastrati A, Windecker S, Valgimigli M, Dangas GD, Von Birgelen C, Smits PC, Kandzari D, Galatius S, Wijns W, Steg PG, Stefanini GG, Aquino M, Morice MC, Camenzind E, Weisz G, Jeger RV, Kimura T, Mikhail GW, Itchhaporia D, Mehta L, Ortega R, Kim HS, Chieffo A, Mehran R.

JACC Cardiovasc Interv. 2016 Sep 26;9(18):1890-901. doi: 10.1016/j.jcin.2016.06.022.

37.

Acute Gain in Minimal Lumen Area Following Implantation of Everolimus-Eluting ABSORB Biodegradable Vascular Scaffolds or Xience Metallic Stents: Intravascular Ultrasound Assessment From the ABSORB II Trial.

Sotomi Y, Ishibashi Y, Suwannasom P, Nakatani S, Cho YK, Grundeken MJ, Zeng Y, Tateishi H, Smits PC, Barragan P, Kornowski R, Gershlick AH, Windecker S, van Geuns RJ, Bartorelli AL, de Winter RJ, Tijssen J, Serruys PW, Onuma Y.

JACC Cardiovasc Interv. 2016 Jun 27;9(12):1216-27. doi: 10.1016/j.jcin.2016.03.022. Epub 2016 Jun 20.

38.

Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization: From the WIN-DES Collaborative Patient-Level Pooled Analysis.

Giustino G, Baber U, Aquino M, Sartori S, Stone GW, Leon MB, Genereux P, Dangas GD, Chandrasekhar J, Kimura T, Salianski O, Stefanini GG, Steg PG, Windecker S, Wijns W, Serruys PW, Valgimigli M, Morice MC, Camenzind E, Weisz G, Smits PC, Kandzari DE, Galatius S, Von Birgelen C, Saporito R, Jeger RV, Mikhail GW, Itchhaporia D, Mehta L, Ortega R, Kim HS, Kastrati A, Chieffo A, Mehran R.

JACC Cardiovasc Interv. 2016 Apr 11;9(7):674-84. doi: 10.1016/j.jcin.2015.12.013.

39.

Impact of percutaneous coronary intervention timing on 5-year outcome in patients with non-ST-segment elevation acute coronary syndromes. The 'wait a day' approach might be safer.

Oosterwerff EF, Fagel ND, Slagboom T, Tijssen JG, Herrman JP, Smits PC, Suttorp MJ, Ronner E, Laarman GJ, Patterson MS, Amoroso G, Vink MA, van der Schaaf RJ, Verheugt FW, Riezebos RK.

Neth Heart J. 2016 Mar;24(3):173-80. doi: 10.1007/s12471-016-0803-0.

40.

Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: A Patient-Level Pooled Analysis of Randomized Controlled Trials.

Baber U, Giustino G, Sartori S, Aquino M, Stefanini GG, Steg PG, Windecker S, Leon MB, Wijns W, Serruys PW, Valgimigli M, Stone GW, Dangas GD, Morice MC, Camenzind E, Weisz G, Smits PC, Kandzari D, Von Birgelen C, Mastoris I, Galatius S, Jeger RV, Kimura T, Mikhail GW, Itchhaporia D, Mehta L, Ortega R, Kim HS, Kastrati A, Chieffo A, Mehran R.

JACC Cardiovasc Interv. 2016 Jan 11;9(1):28-38. doi: 10.1016/j.jcin.2015.09.023.

41.

Safety and Efficacy of New-Generation Drug-Eluting Stents in Women at High Risk for Atherothrombosis: From the Women in Innovation and Drug-Eluting Stents Collaborative Patient-Level Pooled Analysis.

Giustino G, Baber U, Salianski O, Sartori S, Stone GW, Leon MB, Aquino M, Stefanini GG, Steg PG, Windecker S, O' Donoghue M, Wijns W, Serruys PW, Valgimigli M, Morice MC, Camenzind E, Weisz G, Smits PC, Kandzari D, Von Birgelen C, Dangas GD, Cha JY, Galatius S, Jeger RV, Kimura T, Mikhail GW, Itchhaporia D, Mehta L, Ortega R, Kim HS, Kastrati A, Genereux P, Chieffo A, Mehran R.

Circ Cardiovasc Interv. 2016 Jan;9(1):e002995. doi: 10.1161/CIRCINTERVENTIONS.115.002995.

42.

Comparison of endothelium-dependent and -independent vasomotor response after abluminal biodegradable polymer biolimus-eluting stent and persistent polymer everolimus-eluting stent implantation (COMPARE-IT).

Puricel S, Kallinikou Z, Espinola J, Arroyo D, Goy JJ, Stauffer JC, Baeriswyl G, Smits PC, Cook S, Togni M.

Int J Cardiol. 2016 Jan 1;202:525-31. doi: 10.1016/j.ijcard.2015.09.085. Epub 2015 Sep 26.

PMID:
26440470
43.

Final 5-Year Follow-Up of a Randomized Controlled Trial of Everolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice: The COMPARE Trial (A Trial of Everolimus-Eluting Stents and Paclitaxel Stents for Coronary Revascularization in Daily Practice).

Smits PC, Vlachojannis GJ, McFadden EP, Royaards KJ, Wassing J, Joesoef KS, van Mieghem C, van de Ent M.

JACC Cardiovasc Interv. 2015 Aug 17;8(9):1157-1165. doi: 10.1016/j.jcin.2015.03.028. Epub 2015 Jul 22.

44.
45.

Impact of Clinical Presentation (Stable Angina Pectoris vs Unstable Angina Pectoris or Non-ST-Elevation Myocardial Infarction vs ST-Elevation Myocardial Infarction) on Long-Term Outcomes in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents.

Giustino G, Baber U, Stefanini GG, Aquino M, Stone GW, Sartori S, Steg PG, Wijns W, Smits PC, Jeger RV, Leon MB, Windecker S, Serruys PW, Morice MC, Camenzind E, Weisz G, Kandzari D, Dangas GD, Mastoris I, Von Birgelen C, Galatius S, Kimura T, Mikhail G, Itchhaporia D, Mehta L, Ortega R, Kim HS, Valgimigli M, Kastrati A, Chieffo A, Mehran R.

Am J Cardiol. 2015 Sep 15;116(6):845-52. doi: 10.1016/j.amjcard.2015.06.010. Epub 2015 Jun 24.

PMID:
26174605
46.

Long-Term Safety of Drug-Eluting and Bare-Metal Stents: Evidence From a Comprehensive Network Meta-Analysis.

Palmerini T, Benedetto U, Biondi-Zoccai G, Della Riva D, Bacchi-Reggiani L, Smits PC, Vlachojannis GJ, Jensen LO, Christiansen EH, Berencsi K, Valgimigli M, Orlandi C, Petrou M, Rapezzi C, Stone GW.

J Am Coll Cardiol. 2015 Jun 16;65(23):2496-507. doi: 10.1016/j.jacc.2015.04.017.

47.

Long-term follow-up of second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction: three-year results of the XAMI trial.

Hofma SH, Smits PC, Brouwer J, Velders MA, van 't Hof AW, Queré M, de Vries CJ, van Boven AJ.

EuroIntervention. 2015 Mar;10(11):1280-3. doi: 10.4244/EIJY15M01_03.

48.

Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).

Onuma Y, Serruys PW, Muramatsu T, Nakatani S, van Geuns RJ, de Bruyne B, Dudek D, Christiansen E, Smits PC, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Garcia-Garcia HM, Veldhof S, Rapoza R, Ormiston JA.

JACC Cardiovasc Interv. 2014 Dec;7(12):1400-11. doi: 10.1016/j.jcin.2014.06.016.

49.

Everolimus- and sirolimus-eluting stents in patients with and without ST-segment elevation myocardial infarction.

Velders MA, van Boven AJ, Brouwer J, Smits PC, van 't Hof AW, de Vries CJ, Queré M, Hofma SH.

Neth Heart J. 2014 Apr;22(4):167-73. doi: 10.1007/s12471-014-0525-0.

50.

STEMI patients and non-culprit lesions: what to do and when?

Smits PC.

EuroIntervention. 2013 Dec;9(8):895, 897. doi: 10.4244/EIJV9I8A150. No abstract available.

Supplemental Content

Loading ...
Support Center